New data from ASCO 2025 & clinical performance of Natera’s ultra-sensitive MRD platform

Natera and its collaborators presented >6 oral presentations and >25 posters at ASCO 2025, highlighting the growing impact of circulating tumor DNA (ctDNA) in oncology drug development and clinical decision-making.

This webinar will review new data supporting the use of ctDNA-based molecular disease monitoring to enable patient stratification and early response assessment across solid tumors.

Featured data highlights:

• Clinical performance of the Signatera™ Genome assay: 100% specificity and 94% longitudinal sensitivity in a pan-cancer cohort, with analytical detection down to 1 part-per-million (ppm) (George M., et al). Signatera™ Genome is the first and only WGS-based MRD assay to be covered by Medicare.
• ctDNA dynamics in perioperative muscle-invasive bladder cancer (MIBC) from the phase III NIAGARA trial (Powles T., et al)
• Response monitoring in metastatic breast cancer across treatments–including ADCs, CDK4/6i–where ctDNA dynamics were the strongest predictor of treatment benefit (Razavi P., et al)
• Interim findings from DARE, a prospective interventional study, demonstrating feasibility of randomization upon detection of molecular disease (Pusztai L., et al)

Other data presented spanned additional tumor types, including colorectal, gastroesophageal, melanoma, bladder, ovarian, pancreatic, HCC, sarcoma, and others.

Join medical and scientific experts to explore how Natera’s ctDNA platform—anchored by technological innovation, robust clinical evidence, and enabled by extensive commercial infrastructure—is shaping the future of precision oncology trials and clinical decision-making.